Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-27

Study Completion Date

2023-07-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial studies the side effects of tagraxofusp in treating patients with blastic plasmacytoid dendritic cell neoplasm after stem cell transplant. Tagraxofusp is a type of immunotoxin that is made by linking a protein called IL-3 to a toxic substance. Tagraxofusp may help find cancer cells that express IL-3 and kill them without harming normal cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

NCT05720988

Acute Myeloid Leukemia

WITHDRAWN PHASE1

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML

NCT05716009

Acute Myeloid Leukemia

ACTIVE_NOT_RECRUITING PHASE1

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

NCT05233618

Myelofibrosis Chronic Myelomonocytic Leukemia Acute Myeloid Leukemia

RECRUITING PHASE1

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

NCT07137481

Hematological Malignancies

NOT_YET_RECRUITING PHASE2

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

NCT01028716

Acute Biphenotypic Leukemia Acute Erythroid Leukemia in Remission Acute Leukemia in Remission +27 more

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To evaluate the safety of tagraxofusp-erzs (tagraxofusp) in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) after autologous (auto) or allogeneic (allo) hematopoietic cell transplantation (HCT).

SECONDARY OBJECTIVES:

I. To estimate progression-free survival (PFS) in patients with BPDCN receiving maintenance therapy with tagraxofusp after auto-HCT or allo-HCT.

II. To estimate the overall survival (OS) in patients with BPDCN receiving maintenance therapy with tagraxofusp after auto-HCT or allo-HCT.

OUTLINE:

Within day 45 and 180 after stem cell transplant, patients receive tagraxofusp-erzs intravenously (IV) over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for up to 1 year.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blastic Plasmacytoid Dendritic Cell Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (tagraxofusp-erzs)

Within day 45 and 180 after stem cell transplant, patients receive tagraxofusp-erzs IV over 15 minutes on days 1-3 of cycles 1-4 and days 1-2 of subsequent cycles. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.

Group Type EXPERIMENTAL

Tagraxofusp-erzs

Intervention Type BIOLOGICAL

Given IV

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tagraxofusp-erzs

Given IV

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Diphtheria Toxin(388)-Interleukin-3 Fusion Protein DT(388)-IL3 Fusion Protein DT388IL3 fusion protein Elzonris IL3R-targeting Fusion Protein SL-401 SL-401 Tagraxofusp Tagraxofusp ERZS

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Eligible patients will be aged \>= 18 years. Pediatric patients age 2 years and older will be considered on a case by case basis.
* Diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN) according to World Health Organization (WHO) classification or confirmed by hematopathology
* The patients must be in partial response or better
* \> 30 days post-transplant without active or chronic infections
* Karnofsky performance status \>= 60%; Lansky \>= 60
* Left ventricular ejection fraction (LVEF) \>= institutional lower limit of normal by multigated acquisition (MUGA) scan or echocardiogram within 30 days of first protocol treatment
* Diffusion capacity of the lung for carbon monoxide (DLCO) \> 40% of predicted value (corrected for hemoglobin) within 3 months of registration
* Forced expiratory volume in 1 second (FEV1) \> 40% of predicted value within 3 months of registration
* Forced vital capacity (FVC) \> 40% of predicted value within 3 months of registration
* Serum creatinine =\< 1.5 mg/dL (133 mmol/L)
* Serum albumin \>= 3.2 g/dL (or \>= 32 g/L) without IV albumin within the previous 72 hours
* Bilirubin =\< 1.5 x the upper limit of normal (\[ULN\] except patients with Gilbert syndrome in whom bilirubin level of \> 1.5 x ULN will be allowed)
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 times ULN
* Hemoglobin \>= 8 g/dL with or without transfusion in the last 7 days
* Absolute neutrophil count (ANC) \>= 1000 without granulocyte colony stimulating factor (GCSF) or granulocyte-macrophage colony-stimulating factor (GMCSF) in the last 2 weeks prior to screening
* Platelets \>= 50,000micro/mL
* For allo-HCT, no \>= grade 2 visceral (gut or liver) acute graft versus host disease (GVHD) and no \>= grade 3 or any other acute GVHD (patients with chronic GVHD will be allowed at the discretion of the investigator)
* Patient agrees to use acceptable contraceptive methods for the duration of time in the study, and to continue to use acceptable contraceptive methods for 2 months after the last tagraxofusp infusion
* Woman of child bearing potential (WOCBP) with a negative serum or urine pregnancy test within 14 days of tagraxofusp treatment
* Patient or patient's legal representative, parent(s) or guardian able to sign informed consent
* The patient can adhere to the study visit schedule and other protocol requirements, including follow-up for survival assessment

Exclusion Criteria

* The patient has persistent clinically significant non-hematologic toxicities \>= grade 2 (excluding alopecia, nausea, and fatigue)
* Evidence of central nervous system (CNS) involvement
* Uncontrolled and active pulmonary disease
* Requirement for oxygen treatment
* Receiving chemotherapy, radiotherapy or other anti-cancer therapy within 14 days of first dose of study drug. There must be at least a 6-week interval from the last immunotherapy therapy
* Uncontrolled infection
* Human immunodeficiency virus (HIV)/hepatitis B and/or C
* Any history of invasive malignancy in the last 2 years excluding any malignancy such as cervical cancer or skin cancer (excluding melanoma) that is considered cured at the time of screening
* Pregnant or breast-feeding woman
* Patient has uncontrolled intercurrent illness or medical/psychiatric condition that would limit compliance with study requirements or that would in the investigator's opinion place the patient at an unacceptably high risk for toxicities
* Clinical significant cardiopulmonary disease including uncontrolled or New York Heart Association (NYHA) class 3 or 4 congestive heart failure, uncontrolled angina, uncontrolled hypertension, uncontrolled arrhythmia, myocardial infarction or stroke within 6 months of first protocol treatment or corrected QT (QTc) \> 480 ms

Minimum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No